Back grey_arrow_rt.gif
BMS and Sanofi backed by US court on Plavix
Sanofi-Aventis and Bristol-Myers Squibb were celebrating after a US appeals court upheld an injunction that stops rival Apotex from selling a generic version of the firms' blockbuster blood-thinner Plavix.
The decision upheld an earlier court ruling that stops sales of generic Plavix (clopidogrel) until a judge can rule on the validity of one of the compound's patents. That trial is scheduled to start on January 22.
Sales of Plavix collapsed in the third quarter of 2006 after Canada's Apotex flooded the market with a six-month supply of generic clopidogrel in August. Given that Plavix was the second biggest-seller in the world last year, behind Pfizer's Lipitor (atorvastatin), the effect on Sanofi and B-MS has been dramatic.
The Plavix cases have proved particularly dramatic for B-MS, which had earlier signed a deal with Apotex to keep its copycat version of the blood thinner off the market in the USA until September 2011. That pact was overturned by US regulators, prompting Apotex to launch its version anyway and, although an injunction was put in place, the Canadian firm did not have to recall its product.
Sanofi and B-MS issued a statement saying they believe that "the Apotex generic product infringes their intellectual property rights, which they continue to vigorously defend in the pending patent litigation.''
  icon paper stack View Older Articles   Back to Top